FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309737669> ?p ?o ?g. }

• W4309737669 endingPage "8015" @default.
• W4309737669 startingPage "8015" @default.
• W4309737669 abstract "Primary liver cancer is the fifth leading death of cancers in men, and hepatocellular carcinoma (HCC) accounts for approximately 90% of all primary liver cancer cases. Sorafenib is a first-line drug for advanced-stage HCC patients. Sorafenib is a multi-target kinase inhibitor that blocks tumor cell proliferation and angiogenesis. Despite sorafenib treatment extending survival, some patients experience side effects, and sorafenib resistance does occur. 3-Hydroxymethyl glutaryl-CoA synthase 2 (HMGCS2) is the rate-limiting enzyme for ketogenesis, which synthesizes the ketone bodies, β-hydroxybutyrate (β-HB) and acetoacetate (AcAc). β-HB is the most abundant ketone body which is present in a 4:1 ratio compared to AcAc. Recently, ketone body treatment was found to have therapeutic effects against many cancers by causing metabolic alternations and cancer cell apoptosis. Our previous publication showed that HMGCS2 downregulation-mediated ketone body reduction promoted HCC clinicopathological progression through regulating c-Myc/cyclin D1 and caspase-dependent signaling. However, whether HMGCS2-regulated ketone body production alters the sensitivity of human HCC to sorafenib treatment remains unclear. In this study, we showed that HMGCS2 downregulation enhanced the proliferative ability and attenuated the cytotoxic effects of sorafenib by activating expressions of phosphorylated (p)-extracellular signal-regulated kinase (ERK), p-P38, and p-AKT. In contrast, HMGCS2 overexpression decreased cell proliferation and enhanced the cytotoxic effects of sorafenib in HCC cells by inhibiting ERK activation. Furthermore, we showed that knockdown HMGCS2 exhibited the potential migratory ability, as well as decreasing zonula occludens protein (ZO)-1 and increasing c-Myc expression in both sorafenib-treated Huh7 and HepG2 cells. Although HMGCS2 overexpression did not alter the migratory effect, expressions of ZO-1, c-Myc, and N-cadherin decreased in sorafenib-treated HMGCS2-overexpressing HCC cells. Finally, we investigated whether ketone treatment influences sorafenib sensitivity. We showed that β-HB pretreatment decreased cell proliferation and enhanced antiproliferative effect of sorafenib in both Huh7 and HepG2 cells. In conclusion, this study defined the impacts of HMGCS2 expression and ketone body treatment on influencing the sorafenib sensitivity of liver cancer cells." @default.
• W4309737669 created "2022-11-29" @default.
• W4309737669 creator A5016191281 @default.
• W4309737669 creator A5025065015 @default.
• W4309737669 creator A5025159311 @default.
• W4309737669 creator A5054284346 @default.
• W4309737669 creator A5060990393 @default.
• W4309737669 creator A5064513716 @default.
• W4309737669 date "2022-11-18" @default.
• W4309737669 modified "2023-10-09" @default.
• W4309737669 title "HMGCS2 Mediation of Ketone Levels Affects Sorafenib Treatment Efficacy in Liver Cancer Cells" @default.
• W4309737669 cites W1720088159 @default.
• W4309737669 cites W1780842662 @default.
• W4309737669 cites W1967493589 @default.
• W4309737669 cites W1971490477 @default.
• W4309737669 cites W1979598064 @default.
• W4309737669 cites W2002433286 @default.
• W4309737669 cites W2008125452 @default.
• W4309737669 cites W2016252040 @default.
• W4309737669 cites W2022554606 @default.
• W4309737669 cites W2030958875 @default.
• W4309737669 cites W2063488708 @default.
• W4309737669 cites W2082244444 @default.
• W4309737669 cites W2098358937 @default.
• W4309737669 cites W2100592123 @default.
• W4309737669 cites W2131108298 @default.
• W4309737669 cites W2139718640 @default.
• W4309737669 cites W2147748185 @default.
• W4309737669 cites W2150384392 @default.
• W4309737669 cites W2155631120 @default.
• W4309737669 cites W2170884400 @default.
• W4309737669 cites W2310597351 @default.
• W4309737669 cites W2407812106 @default.
• W4309737669 cites W2414362226 @default.
• W4309737669 cites W2562858475 @default.
• W4309737669 cites W2587156779 @default.
• W4309737669 cites W2590914912 @default.
• W4309737669 cites W2591785182 @default.
• W4309737669 cites W2593797738 @default.
• W4309737669 cites W2594618407 @default.
• W4309737669 cites W2598230851 @default.
• W4309737669 cites W2730778804 @default.
• W4309737669 cites W2752053733 @default.
• W4309737669 cites W2767848831 @default.
• W4309737669 cites W2787358630 @default.
• W4309737669 cites W2923414181 @default.
• W4309737669 cites W2969579527 @default.
• W4309737669 cites W2969802526 @default.
• W4309737669 cites W2984732042 @default.
• W4309737669 cites W2990060012 @default.
• W4309737669 cites W2990365739 @default.
• W4309737669 cites W3005739154 @default.
• W4309737669 cites W3008847232 @default.
• W4309737669 cites W3022401518 @default.
• W4309737669 cites W3040614614 @default.
• W4309737669 cites W3041333070 @default.
• W4309737669 cites W3045763822 @default.
• W4309737669 cites W3087077238 @default.
• W4309737669 cites W3103776403 @default.
• W4309737669 cites W3119005666 @default.
• W4309737669 cites W3137220512 @default.
• W4309737669 cites W3138103967 @default.
• W4309737669 cites W3141843243 @default.
• W4309737669 cites W3168097989 @default.
• W4309737669 cites W3176618720 @default.
• W4309737669 cites W3187240233 @default.
• W4309737669 cites W3195078286 @default.
• W4309737669 cites W3198419784 @default.
• W4309737669 cites W4213314804 @default.
• W4309737669 cites W4225100118 @default.
• W4309737669 cites W4286587514 @default.
• W4309737669 cites W4289523139 @default.
• W4309737669 cites W53611414 @default.
• W4309737669 doi "https://doi.org/10.3390/molecules27228015" @default.
• W4309737669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36432116" @default.
• W4309737669 hasPublicationYear "2022" @default.
• W4309737669 type Work @default.
• W4309737669 citedByCount "3" @default.
• W4309737669 countsByYear W43097376692023 @default.
• W4309737669 crossrefType "journal-article" @default.
• W4309737669 hasAuthorship W4309737669A5016191281 @default.
• W4309737669 hasAuthorship W4309737669A5025065015 @default.
• W4309737669 hasAuthorship W4309737669A5025159311 @default.
• W4309737669 hasAuthorship W4309737669A5054284346 @default.
• W4309737669 hasAuthorship W4309737669A5060990393 @default.
• W4309737669 hasAuthorship W4309737669A5064513716 @default.
• W4309737669 hasBestOaLocation W43097376691 @default.
• W4309737669 hasConcept C104317684 @default.
• W4309737669 hasConcept C121608353 @default.
• W4309737669 hasConcept C126322002 @default.
• W4309737669 hasConcept C127561419 @default.
• W4309737669 hasConcept C134018914 @default.
• W4309737669 hasConcept C184235292 @default.
• W4309737669 hasConcept C190283241 @default.
• W4309737669 hasConcept C2776231280 @default.
• W4309737669 hasConcept C2778019345 @default.
• W4309737669 hasConcept C2778695046 @default.
• W4309737669 hasConcept C502942594 @default.

• next